
Purpose:Rheumatoid arthritis (RA) affects women two-three times more frequently than men, and registries report sex-based differences in disease activity and remission. However, sex-stratified outcome data from Saudi Arabia are limited. We evaluated sex differences in disease activity, remission rates, and predictors of remission in the Rheumatoid Arthritis Saudi Database (RASD). Patients and Methods:We conducted a prospective cohort study of 647 patients with RA receiving biological or targeted synthetic DMARDs (574 female and 73 male) with at least 12 months of follow-up. Disease activity was assessed using DAS28-CRP, CDAI, FSS, and HAQ-DI across three visits. Remission was defined as DAS28-CRP <2.6. Linear mixed-effects models examined disease activity trajectories by sex, and multivariable logistic regression identified predictors of remission at visit 3. Benjamini-Hochberg correction was applied across six Stage-4 chi-square tests and across three pairwise sex comparisons within each outcome. Results:Overall remission rates rose from 50.9% at visit 1 to 83.5% at visit 3, with no significant sex differences after correction for multiple comparisons. DAS28-CRP declined significantly over time in both sexes (p <0.001). Males had higher adjusted CDAI at Visit 1 (13.43 vs 11.12; BH-adjusted p = 0.007), but not at visits 2 or 3; the visit-by-sex interaction was significant (unadjusted Type III p = 0.032). Fatigue and functional disability did not differ by sex. ACPA positivity was associated with higher odds of remission (OR 1.67, 95% CI 1.03-2.68, p = 0.036), while RF positivity was associated with lower odds (OR 0.61, 95% CI 0.38-0.96; p = 0.034). Sex was not an independent predictor. Conclusion:In this Saudi RA cohort, both sexes achieved high remission rates under treat-to-target management, and sex differences in disease activity did not persist after multiple-comparison correction. RF and ACPA, rather than sex, were the dominant predictors of remission.
Purpose:To describe the clinical features of patients with idiopathic inflammatory myopathies (IIM) and report the prevalence of malignancy among them within a single-center cohort in southwestern Saudi Arabia. Patients and Methods:We conducted a retrospective study at Aseer Central Hospital, reviewing records of patients diagnosed with IIM according to the ACR/EULAR 2017 classification criteria over a five-year period (January 2021-December 2025). Demographic, clinical, laboratory, and treatment data were collected and analyzed using appropriate statistical tests. Results:Twenty-nine patients were included (75.9% female; mean age 41.9 years). Dermatomyositis (DM, 12/29, 41.4%) predominated, followed by polymyositis (PM, 10/29, 34.5%) and antisynthetase syndrome (ASA, 7/29, 24.1%). Skin manifestations were observed in all DM patients, with isolated involvement in one ASA patient (100% DM vs 0.0% PM vs 14.3% ASA; p < 0.001). Creatine phosphokinase (CPK) was significantly higher in PM and ASA versus DM (medians 4884 and 6334 vs 316 U/L; p = 0.005). Interstitial lung disease (ILD) was most prevalent in ASA (71.4% vs 20.0% PM vs 16.7% DM; p = 0.029). Two females with DM aged ≥40 years developed malignancy (ovarian and breast; 2/29, 6.9%). Anti-Jo1 antibodies were present in 7 of 27 tested patients (25.9%), and were significantly associated with ILD (71.4% vs 20.0%, p = 0.023). No malignancy occurred in patients with ILD or anti-Jo1 positivity. Full muscle strength recovery was achieved in 26 of 29 patients (89.7%), though 10 of 29 patients (34.5%) required escalation to intravenous immunoglobulin and/or rituximab for refractory disease. Conclusion:Malignancy prevalence (2/29 patients, 6.9%) aligns with recent Saudi data but is lower than that reported in East Asian and many Western reports. In this study, cancer occurred exclusively in DM patients aged ≥ 40 years, lacking ILD or anti-Jo1 antibodies, consistent with established risk patterns. These findings support a clinically guided approach to cancer screening, particularly in patients with DM.
Background:Endothelial and microvascular damage is a hallmark of systemic sclerosis (SSc), an autoimmune connective tissue disease characterized by progressive skin and organ fibrosis. Aminaphtone (3-Methyl-1,4-dioxo-1,4-dihydro-naphthalen-2-yl-amino-benzoate) is a synthetic molecule used to treat microvascular disorders. Nailfold videocapillaroscopy (NVC) is the most reliable non-invasive method for assessing microvascular status and disease progression in SSc patients. Aim:To evaluate long-term safety and potential beneficial effects of aminaphtone on microcirculation in SSc. Methods:Seventy-six SSc patients (68 females, 8 males; mean age 69 ± 15 years) fulfilling the 2013 ACR/EULAR criteria and presenting Raynaud's phenomenon received aminaphtone (75 mg twice daily) in addition to stable standard therapy (ST). Forty age- and sex-matched SSc patients treated with ST alone served as controls. Side effects were monitored every six months. NVC was performed at baseline and after 1 and 4 years, using the Cutolo classification ("Early", "Active", "Late" patterns) to evaluate microvascular damage progression. Results:Aminaphtone showed a high long-term retention rate (89.5%) over four years. Eight of 76 patients (10.5%) discontinued treatment due to mild transient intolerance or poor compliance; no serious adverse events were reported. NVC patterns remained stable in 91% of treated patients. Compared with controls, aminaphtone-treated patients showed a slower transition from "Active" to "Late" NVC pattern (120 ± 64 vs 50 ± 26 months, p = 0.05). Linear mixed-effects modelling showed a significantly slower capillary density decline in the aminaphtone group over 48 months (p < 0.05) in both "Early" and "Active" scleroderma pattern subgroups. On multivariate linear regression, this effect was independent of age, disease phenotype, and concomitant therapies. Conclusion:Aminaphtone appears safe and well tolerated during long-term treatment in SSc patients with secondary Raynaud's phenomenon. The stability of NVC scleroderma patterns and the independent protective effect on capillary loss suggest a potential adjunctive role of aminaphtone in limiting microvascular damage progression when added to ST in SSc.
Background:Autoantibody testing supports the diagnosis of systemic autoimmune diseases, but indiscriminate use in low pre-test probability settings can reduce test positivity and inflate direct laboratory costs. Hospital-wide audits of real-world ordering practices across specialties remain scarce and, to our knowledge, have not been reported in the Gulf region. Objectives:To describe the test positivity rate, direct laboratory cost, and departmental variation of hospital-wide autoantibody testing in a tertiary center in the Eastern Province of Saudi Arabia. Methods:We conducted a retrospective hospital-wide audit of all autoantibody tests ordered across 15 clinical departments at King Fahd University Hospital between 1 January and 30 April 2024. Test volumes, positivity rates, and direct laboratory costs were summarized at departmental and subspecialty levels. Rheumatology was compared with all non-rheumatology services as a pre-specified inferential contrast using chi-square or Fisher exact tests with 95% Wilson confidence intervals and Benjamini-Hochberg adjustment across per-marker comparisons; the unit of analysis was the test order. Results:A total of 5973 autoantibody tests were performed in 1059 patients, with an overall test positivity rate of 16.3% (95% CI 15.4-17.2). Total direct laboratory expenditure was USD 509,136, of which 87% was attributable to negative results. Test positivity ranged from 26% in Pediatrics to ≤7% in Neurology and Neurosurgery. Rheumatology had a higher positivity rate (24.4%, 95% CI 22.2-26.8) than non-rheumatology services combined (13.9%, 95% CI 12.9-14.9; p<0.001), with the largest absolute differences for antinuclear antibodies (88.7% vs 35.7%; p<0.001) and SSA antibodies (27.9% vs 5.9%; p<0.001). Direct cost per positive result was USD 364 in Rheumatology versus USD 606 in non-rheumatology services. Conclusions:In this single-center audit, autoantibody ordering practices clustered into two descriptive patterns: hypothesis-driven, higher-positivity testing within specialist care and broader, lower-positivity panel use in several non-specialist services. These differences were statistically significant and most plausibly reflect more disciplined application of pre-test probability by specialists, although referral filtering and case-mix differences contribute and cannot be fully separated from clinician-level reasoning in this dataset. These patterns suggest that targeted diagnostic stewardship-reflex-cascade algorithms, order-menu redesign, and indication-based gating-could concentrate autoantibody testing where pre-test probability is highest, improving positivity and reducing avoidable cost without restricting clinical access.
Purpose: Rheumatoid arthritis (RA) management emphasizes treat-to-target strategies with timely escalation from conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to biologic (bDMARDs) or targeted synthetic DMARDs (tsDMARDs) when remission or low disease activity is not achieved. Comparative real-world effectiveness evidence across advanced therapies remains limited in some settings. To compare 12-month outcomes and treatment persistence across biologic (bDMARD) and targeted synthetic DMARDs (tsDMARDs) in Saudi patients enrolled in the Rheumatoid Arthritis Saudi Database (RASD). Patients and Methods: We conducted a prospective multicenter cohort study of RASD patients receiving biologic or targeted synthetic DMARDs, with a minimum follow-up of 12 months and assessments at baseline, 3-6 months, and 12 months. Outcomes included longitudinal DAS28-CRP change, 12-month disease activity, function, fatigue, remission, and treatment persistence through 36 months. Analyses used mixed-effects, covariate-adjusted regression, ordinal regression, logistic regression, and Kaplan-Meier methods, as appropriate for each outcome. Results: We analyzed 647 treatment courses across nine advanced therapies. Disease activity improved significantly over time, with a strong overall DAS28-CRP time effect (p<0.0001), but no significant overall drug effect (p=0.327) or time-by-drug interaction (p=0.218). Model-estimated 12-month DAS28-CRP values were closely clustered across therapies, with overlapping confidence intervals and no significant pairwise differences. In adjusted 12-month analyses, DAS28-CRP, CDAI, fatigue severity, and remission were comparable across agents. Most adjusted between-drug comparisons were non-significant, except for worse HAQ category with certolizumab compared with tofacitinib (adjusted OR 2.45, 95% CI 1.12-5.37). Remission varied significantly across participating centers. Discontinuation rates were low, most commonly due to lack of efficacy, and treatment persistence did not differ significantly across therapies through 36 months (log-rank p=0.17). Conclusion: Advanced RA therapies were associated with significant disease activity improvement and minimal adjusted between-drug differences. Except for an isolated worse HAQ signal with certolizumab versus tofacitinib, outcomes were broadly comparable across agents. Center-level remission variation highlights the importance of standardized treat-to-target implementation. Trial Registration: ClinicalTrials.gov Identifier: NCT06417138.